Evox Therapeutics, an Oxford, England, UK-based exosome therapeutics company, secured £1.5m in funding.
Backers included Innovate UK, the UK’s Innovation Agency, through the Biomedical Catalyst Early Stage Award.
The company intends to use the funds for pre-clinical development of an exosome-based therapy to treat argininosuccinic aciduria (ASA), a rare life-threatening metabolic disease, in collaboration with University College London (UCL).
Led by Dr Antonin de Fougerolles, Chief Executive Officer, and Dr Per Lundin, Co-Founder & Chief Operating Officer, Evox is engineering exosomes, the body’s natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood-brain barrier to deliver drugs to the central nervous system, enabling intracellular delivery of biologics, and allowing for extra-hepatic delivery of RNA therapeutics. UCL has world-leading expertise in urea cycle disorders and will perform testing of Evox’s exosome-based therapy in an in vivo ASL deficiency model.